Symbols / IMDX Stock $3.76 +6.82% Insight Molecular Diagnostics Inc.

Healthcare • Diagnostics & Research • United States • NCM
IMDX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Joshua Riggs
Exch · Country NCM · United States
Market Cap 120.95M
Enterprise Value 112.87M
Income -50.22M
Sales 4.05M
FCF (ttm) -14.04M
Book/sh -1.10
Cash/sh 0.36
Employees 55
Insider 10d —
IPO Dec 30, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.48
PEG —
P/S 29.83
P/B -3.43
P/C —
EV/EBITDA -3.99
EV/Sales 27.83
Quick Ratio 1.05
Current Ratio 1.27
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.65
EPS next Y -0.84
EPS Growth —
Revenue Growth -23.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-26
ROA -62.66%
ROE —
ROIC —
Gross Margin 56.84%
Oper. Margin -8.74%
Profit Margin 0.00%
Shs Outstand 32.17M
Shs Float 10.72M
Insider Own 20.09%
Instit Own 55.06%
Short Float 2.67%
Short Ratio 1.34
Short Interest 455.87K
52W High 8.51
vs 52W High -55.82%
52W Low 2.33
vs 52W Low 61.37%
Beta 1.53
Impl. Vol. 1.66%
Rel Volume 1.39
Avg Volume 203.56K
Volume 283.88K
Target (mean) $8.33
Tgt Median $9.00
Tgt Low $4.00
Tgt High $12.00
# Analysts 3
Recom Buy
Prev Close $3.52
Price $3.76
Change 6.82%
About

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.33
Mean price target
2. Current target
$3.76
Latest analyst target
3. DCF / Fair value
$-7.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.76
Low
$4.00
High
$12.00
Mean
$8.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-17 main Lake Street Buy → Buy $12
2025-11-11 main Needham Buy → Buy $9
2025-08-18 reit Needham Buy → Buy $4
2025-05-21 main Lake Street Buy → Buy $8
2025-05-13 reit Needham Buy → Buy $4
2025-04-08 reit Needham Buy → Buy $4
2025-03-28 init Lake Street — → Buy $5
2025-03-26 reit Stephens & Co. Equal-Weight → Equal-Weight $4
2025-03-25 reit Stephens & Co. Equal-Weight → Equal-Weight $4
2025-03-25 reit Needham Buy → Buy $4
News
RSS: Latest IMDX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-20 BROADWOOD PARTNERS, L.P. Beneficial Owner of more than 10% of a Class of Security — 182,861 $3.45 $652,876
2026-03-26 LIU JAMES YANG Officer and Treasurer — 6,289 — —
2026-03-26 RIGGS JOSHUA Chief Executive Officer — 47,170 — —
2026-03-26 JAMES ANDREA S. Chief Financial Officer — 28,302 — —
2026-02-10 BROADWOOD PARTNERS, L.P. Beneficial Owner of more than 10% of a Class of Security — 521,739 $7.41 $3,866,086
2025-10-31 JAMES ANDREA S. Chief Financial Officer — 50,000 — —
2025-10-31 JAMES ANDREA S. Chief Financial Officer — 50,000 — —
2025-07-01 SILVERMAN LOUIS E Director — 35,000 $0.00 $0
2025-07-01 ARNO ANDREW Director — 55,000 $0.00 $0
2025-07-01 LAST ANDREW J Director — 35,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.05
+115.58%
1.88
+25.15%
1.50
+56.89%
0.96
Operating Revenue
4.05
+115.58%
1.88
+25.15%
1.50
+56.89%
0.96
Cost Of Revenue
1.76
+53.99%
1.14
+4.68%
1.09
+11.68%
0.98
Reconciled Cost Of Revenue
0.42
-62.84%
1.14
+4.68%
1.09
+11.68%
0.98
Gross Profit
2.30
+210.54%
0.74
+79.18%
0.41
+2394.44%
-0.02
Operating Expense
32.88
+37.06%
23.99
+5.07%
22.83
-20.82%
28.83
Research And Development
15.90
+61.60%
9.84
+5.86%
9.29
+27.30%
7.30
Selling General And Administration
16.11
+16.88%
13.79
+3.76%
13.29
-38.30%
21.53
Selling And Marketing Expense
1.21
+89.24%
0.64
+108.79%
0.31
+1705.88%
0.02
General And Administrative Expense
14.90
+13.35%
13.14
+1.28%
12.98
-39.68%
21.52
Salaries And Wages
9.90
+30.47%
7.59
+11.13%
6.83
-49.19%
13.44
Other Gand A
3.75
-6.46%
4.01
+14.16%
3.51
-34.20%
5.33
Total Expenses
34.63
+37.83%
25.13
+5.05%
23.92
-19.76%
29.81
Operating Income
-30.58
-31.54%
-23.25
-3.70%
-22.42
+22.30%
-28.85
Total Operating Income As Reported
-51.12
+16.25%
-61.04
-142.84%
-25.14
-39.67%
-18.00
EBITDA
-47.92
+18.81%
-59.02
-155.22%
-23.12
-73.74%
-13.31
Normalized EBITDA
-27.37
-28.98%
-21.22
-4.32%
-20.34
+14.14%
-23.69
Reconciled Depreciation
2.20
+40.47%
1.56
-6.90%
1.68
-67.82%
5.22
EBIT
-50.11
+17.28%
-60.58
-144.24%
-24.80
-33.86%
-18.53
Total Unusual Items
-20.55
+45.64%
-37.79
-1259.50%
-2.78
-126.77%
10.38
Total Unusual Items Excluding Goodwill
-20.55
+45.64%
-37.79
-1259.50%
-2.78
-126.77%
10.38
Special Income Charges
-20.55
+45.64%
-37.79
-1290.00%
-2.72
-125.05%
10.86
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
14.60
-65.16%
41.90
+520.10%
6.76
-63.84%
18.68
Restructuring And Mergern Acquisition
5.95
+239.09%
-4.28
+19.66%
-5.32
+81.99%
-29.54
Write Off
0.00
-100.00%
0.17
-86.83%
1.28
—
Net Income
-50.22
+17.21%
-60.66
-118.36%
-27.78
+61.89%
-72.90
Pretax Income
-50.22
+17.21%
-60.66
-144.07%
-24.86
-33.54%
-18.61
Net Non Operating Interest Income Expense
-0.11
-29.76%
-0.08
-61.54%
-0.05
+37.35%
-0.08
Interest Expense Non Operating
0.11
+29.76%
0.08
+61.54%
0.05
-37.35%
0.08
Net Interest Income
-0.11
-29.76%
-0.08
-61.54%
-0.05
+37.35%
-0.08
Interest Expense
0.11
+29.76%
0.08
+61.54%
0.05
-37.35%
0.08
Other Income Expense
-19.54
+47.67%
-37.33
-1464.63%
-2.39
-123.11%
10.32
Other Non Operating Income Expenses
1.01
+118.83%
0.46
+17.26%
0.39
+745.90%
-0.06
Gain On Sale Of Security
—
—
-0.06
+87.05%
-0.47
Tax Provision
—
—
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-50.22
+17.21%
-60.66
-118.36%
-27.78
+61.89%
-72.90
Net Income From Continuing Operation Net Minority Interest
-50.22
+17.21%
-60.66
-144.07%
-24.86
-33.54%
-18.61
Net Income From Continuing And Discontinued Operation
-50.22
+17.21%
-60.66
-118.36%
-27.78
+61.89%
-72.90
Net Income Continuous Operations
-50.22
+17.21%
-60.66
-144.07%
-24.86
-33.54%
-18.61
Net Income Discontinuous Operations
—
0.00
+100.00%
-2.93
+94.61%
-54.29
Normalized Income
-29.68
-29.77%
-22.87
-3.60%
-22.07
+23.87%
-29.00
Net Income Common Stockholders
-50.22
+17.57%
-60.93
-112.12%
-28.72
+60.88%
-73.42
Otherunder Preferred Stock Dividend
—
—
—
0.52
Diluted EPS
-1.65
+64.59%
-4.66
-24.27%
-3.75
+81.25%
-20.00
Basic EPS
-1.65
+64.59%
-4.66
-24.27%
-3.75
+81.25%
-20.00
Basic Average Shares
30.48
+133.16%
13.07
+70.84%
7.65
+38.10%
5.54
Diluted Average Shares
30.48
+133.16%
13.07
+70.84%
7.65
+38.10%
5.54
Diluted NI Availto Com Stockholders
-50.22
+17.57%
-60.93
-112.12%
-28.72
+60.88%
-73.42
Depreciation Amortization Depletion Income Statement
0.86
+138.02%
0.36
+44.62%
0.25
—
Depreciation And Amortization In Income Statement
0.86
+138.02%
0.36
+44.62%
0.25
—
Earnings From Equity Interest
—
—
—
0.00
Gain On Sale Of PPE
—
—
-1.28
0.00
Insurance And Claims
1.25
-19.34%
1.55
-41.37%
2.64
-3.72%
2.74
Preferred Stock Dividends
—
0.26
-72.08%
0.94
+81.15%
0.52
Line Item Trend 2023-12-31
Total Assets
74.89
Current Assets
10.70
Cash Cash Equivalents And Short Term Investments
9.43
Cash And Cash Equivalents
9.43
Other Short Term Investments
0.00
Receivables
0.48
Accounts Receivable
0.48
Gross Accounts Receivable
0.49
Allowance For Doubtful Accounts Receivable
-0.01
Inventory
0.00
Raw Materials
—
Finished Goods
—
Prepaid Assets
—
Current Deferred Assets
0.00
Restricted Cash
—
Assets Held For Sale Current
0.14
Other Current Assets
0.64
Total Non Current Assets
64.19
Net PPE
5.44
Gross PPE
11.67
Accumulated Depreciation
-6.24
Machinery Furniture Equipment
6.91
Construction In Progress
0.73
Other Properties
4.04
Goodwill And Other Intangible Assets
56.59
Goodwill
—
Other Intangible Assets
56.59
Investments And Advances
—
Long Term Equity Investment
—
Other Non Current Assets
2.16
Total Liabilities Net Minority Interest
54.42
Current Liabilities
7.19
Payables And Accrued Expenses
2.52
Payables
0.95
Accounts Payable
0.95
Current Accrued Expenses
1.57
Pensionand Other Post Retirement Benefit Plans Current
3.96
Current Debt And Capital Lease Obligation
0.67
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.67
Other Current Liabilities
0.04
Total Non Current Liabilities Net Minority Interest
47.23
Long Term Debt And Capital Lease Obligation
2.20
Long Term Capital Lease Obligation
2.20
Other Non Current Liabilities
39.90
Preferred Securities Outside Stock Equity
5.13
Stockholders Equity
20.47
Common Stock Equity
20.47
Capital Stock
310.30
Common Stock
310.30
Preferred Stock
0.00
Share Issued
8.26
Ordinary Shares Number
8.26
Treasury Shares Number
0.00
Retained Earnings
-289.88
Gains Losses Not Affecting Retained Earnings
0.05
Other Equity Adjustments
0.05
Total Equity Gross Minority Interest
20.47
Total Capitalization
20.47
Working Capital
3.50
Invested Capital
20.47
Total Debt
2.87
Capital Lease Obligations
2.87
Net Tangible Assets
-36.13
Tangible Book Value
-36.13
Dueto Related Parties Current
—
Line Of Credit
—
Notes Receivable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-22.18
-7.23%
-20.69
+11.30%
-23.32
+48.81%
-45.57
Cash Flow From Continuing Operating Activities
-22.18
-7.23%
-20.69
+11.30%
-23.32
+48.81%
-45.57
Net Income From Continuing Operations
-50.22
+17.21%
-60.66
-118.36%
-27.78
+61.89%
-72.90
Depreciation Amortization Depletion
2.20
+40.47%
1.56
-6.90%
1.68
-67.82%
5.22
Depreciation
2.19
+48.37%
1.48
-7.29%
1.59
+4.19%
1.53
Amortization Cash Flow
0.01
-92.05%
0.09
+0.00%
0.09
-97.62%
3.69
Depreciation And Amortization
2.20
+40.47%
1.56
-6.90%
1.68
-67.82%
5.22
Amortization Of Intangibles
0.01
-92.05%
0.09
+0.00%
0.09
-97.62%
3.69
Other Non Cash Items
5.95
+239.09%
-4.28
-0.80%
-4.24
+86.32%
-31.01
Pension And Employee Benefit Expense
—
—
—
—
Stock Based Compensation
2.38
+24.57%
1.91
-33.74%
2.89
-71.25%
10.04
Asset Impairment Charge
14.60
-65.30%
42.07
+423.25%
8.04
-81.95%
44.55
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
0.18
+4725.00%
-0.00
-106.56%
0.06
-87.05%
0.47
Gain Loss On Investment Securities
—
—
0.06
-87.05%
0.47
Unrealized Gain Loss On Investment Securities
—
—
—
0.47
Net Foreign Currency Exchange Gain Loss
0.18
+4725.00%
-0.00
—
—
Change In Working Capital
2.73
+310.90%
-1.29
+67.44%
-3.97
-104.48%
-1.94
Change In Receivables
0.48
+142.96%
-1.13
-1135.78%
0.11
+118.96%
-0.57
Changes In Account Receivables
0.48
+142.96%
-1.13
-1135.78%
0.11
+118.96%
-0.57
Change In Inventory
-0.04
+91.22%
-0.41
0.00
—
Change In Prepaid Assets
-0.23
+47.44%
-0.43
-154.85%
0.78
+439.39%
-0.23
Change In Payables And Accrued Expense
2.65
+173.63%
0.97
+120.33%
-4.76
-366.37%
-1.02
Change In Accrued Expense
—
—
0.00
+100.00%
-1.32
Change In Payable
—
—
-4.76
-1701.68%
0.30
Change In Account Payable
—
—
-4.76
-1701.68%
0.30
Change In Other Working Capital
-0.14
+51.20%
-0.29
-171.96%
-0.11
+7.76%
-0.12
Change In Other Current Liabilities
—
—
—
-0.12
Investing Cash Flow
-3.19
-522.07%
-0.51
+45.06%
-0.93
+78.53%
-4.34
Cash Flow From Continuing Investing Activities
-3.19
-522.07%
-0.51
-216.36%
0.44
+110.14%
-4.34
Cash From Discontinued Investing Activities
—
0.00
+100.00%
-1.37
0.00
Net PPE Purchase And Sale
-3.19
-522.07%
-0.51
-801.37%
0.07
+101.68%
-4.34
Purchase Of PPE
-3.19
-517.25%
-0.52
-83.63%
-0.28
+93.53%
-4.34
Sale Of PPE
0.00
-100.00%
0.00
-98.87%
0.35
0.00
Capital Expenditure
-3.19
-517.25%
-0.52
-83.63%
-0.28
+93.53%
-4.34
Net Investment Purchase And Sale
—
0.00
-100.00%
0.37
0.00
Sale Of Investment
—
0.00
-100.00%
0.37
0.00
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Financing Cash Flow
28.07
+37.41%
20.43
+67.64%
12.19
-65.97%
35.81
Cash Flow From Continuing Financing Activities
28.07
+37.41%
20.43
+67.64%
12.19
-65.97%
35.81
Net Issuance Payments Of Debt
-0.51
-154.73%
-0.20
-71.79%
-0.12
+91.81%
-1.43
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.51
-154.73%
-0.20
-71.79%
-0.12
+91.81%
-1.43
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.51
-154.73%
-0.20
-71.79%
-0.12
-12.50%
-0.10
Net Long Term Debt Issuance
-0.51
-154.73%
-0.20
-71.79%
-0.12
-12.50%
-0.10
Short Term Debt Payments
—
—
0.00
+100.00%
-1.32
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-1.32
Net Common Stock Issuance
29.14
+4.78%
27.81
+100.85%
13.85
-57.84%
32.84
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-5.39
-382.02%
-1.12
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
-0.56
+68.86%
-1.79
-320.37%
-0.43
+11.59%
-0.48
Changes In Cash
2.70
+450.13%
-0.77
+93.60%
-12.07
+14.40%
-14.10
Effect Of Exchange Rate Changes
-0.12
-400.00%
-0.02
—
—
Beginning Cash Position
10.34
-7.15%
11.13
-52.02%
23.20
-37.80%
37.30
End Cash Position
12.92
+24.99%
10.34
-7.15%
11.13
-52.02%
23.20
Free Cash Flow
-25.37
-19.64%
-21.20
+10.17%
-23.61
+52.70%
-49.91
Interest Paid Supplemental Data
0.09
+116.67%
0.04
+500.00%
0.01
-70.83%
0.02
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
29.14
+4.78%
27.81
+100.85%
13.85
-57.84%
32.84
Earnings Losses From Equity Investments
—
—
—
0.00
Issuance Of Capital Stock
29.14
+4.78%
27.81
+100.85%
13.85
-63.29%
37.72
Net Preferred Stock Issuance
0.00
+100.00%
-5.39
-382.02%
-1.12
-122.93%
4.88
Preferred Stock Issuance
—
—
0.00
-100.00%
4.88
Preferred Stock Payments
0.00
+100.00%
-5.39
-382.02%
-1.12
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category